DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
NRX Pharmaceuticals Inc ($NRXP)
NRx Pharmaceuticals is a micro-cap biotech focused on severe psychiatric conditions: suicidal depression, bipolar depression with suicidality, PTSD and related disorders. The core of the story is NRX-100, a preservative-free intravenous ketamine program supported by a large Real-World Evidence dataset, and NRX-101, an oral D-cycloserine + lurasidone combination with Breakthrough designation. Around those assets, the company is building HOPE Therapeutics, a network of interventional psychiatry clinics that should both validate the care model and generate revenue.
T1 Energy Inc. ($TE)
Next business catalyst
Late February 2026 – expected Q4 2025 earnings and business update, with more detail on 45X tax credit monetization, Giga America ramp and FEOC-compliant sourcing.
War Ai and the X Ecosystem
SpaceX launches satellites, Starlink keeps front lines online, X shapes the information space, and xAI’s Grok is being wired into military networks. A new Pentagon contest for voice-controlled autonomous drones shows how these pieces are starting to lock together into a single, highly political war-tech stack.
Ocular Therapeutix Inc ($OCUL)
Positive 52-week SOL-1 data position AXPAXLI as a potential long-acting option versus aflibercept, yet the stock sells off as investors question trial design, real-world relevance and the regulatory path.
Castellum Inc ($CTM) Now Debt Free
From heavily leveraged roll-up to cash-rich, debt-free federal contractor: what changes after the last note payoff, how the Navy “Big 3” contracts reshape visibility, and what still can go wrong for shareholders.
ImmunityBio Inc ($IBRX) ANKTIVA in EU Ok!
European Commission Grants Final Conditional Marketing Authorization for ANKTIVA® in EU
Decision C(2026)1197: Final, binding authorization allowing commercial launch across 27 EU member states + Iceland, Norway, Liechtenstein for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
ImmunityBio (IBRX) — Saudi SFDA engagement
Two items in one tape-read: (1) a fresh BusinessWire update on Saudi regulatory engagement (rBCG dossier + ANKTIVA/CPI expansion discussions), and (2) a sell-side note in circulation reiterating a $24 price target from D. Boral Capital (note dated Jan 13, 2026 in the sources below).
Compass Pathways Plc ADR ($CMPS) Updated post CC
Release of new clinical data from two Phase 3 trials (COMP005 and COMP006) on COMP360 in TRD + management webcast
Tradable short-term event: additional clinical data (specific portions of studies) and official management narrative. This is the type of event that changes the perception of probability/quality of clinical evidence, and thus volatility too.
AI in Biotech 2026 $RXRX $TEM $EXAI
Recursion, Tempus AI and Exscientia are three “pure-play” examples of what it really means to put artificial intelligence at the centre of a biotech business model. Used properly, AI can compress timelines, surface non-obvious biology and make better use of messy data. Used badly, it can amplify errors, burn cash faster and create stories the clinic will never confirm.
Precision Biosciences Inc ($DTIL)
Next catalyst
H1 2026 – Updated ELIMINATE-B Phase 1/2 data in chronic hepatitis B (PBGENE-HBV), including higher-dose biopsy readouts.
Secondary 2026 catalyst: first sites activated and initial multi-patient data from the FUNCTION-DMD Phase 1/2 trial of PBGENE-DMD after FDA IND clearance (Study May Proceed) in February 2026.
Aldeyra Therapeutics (ALDX) PDUFA March 2026
Aldeyra Therapeutics (NASDAQ: ALDX) is a clinical-stage biotechnology company developing modulators of reactive aldehyde species (RASP) for immune-mediated and metabolic diseases. The key late-stage asset is reproxalap, an ophthalmic RASP modulator for dry eye disease (DED) and allergic conjunctiviti
2026 Decisive year for three cult biotech stocks $IOVA $IBRX $ALT
A parallel “year of truth” roadmap for Iovance Biotherapeutics (IOVA), ImmunityBio (IBRX) and Altimmune (ALT), three names with huge retail followings, real science on the table and very little room for execution mistakes.
Weekly Market Briefing (February 16–20, 2026)
Wall Street just closed a choppy week where enthusiasm about AI and data-center spend ran into valuation nerves, while inflation data kept the “soft landing” narrative alive. The coming days will be dominated by U.S. GDP, the Fed’s preferred inflation gauge (core PCE), fresh PMIs and a cluster of sector-specific catalysts across biotech, space, defense and AI small/mid caps.
Top 10 AI Mid & Small Cap Stocks for 2026
The logic of this basket is to follow the AI value chain from data to models to deployment, without touching the mega-cap hyperscalers. Each ticker is plugged into a different piece of that chain: some provide platforms, some sell services, some sell hardware that enables AI workloads.
Top 10 Space Mid & Small Caps 2026
A simple way to think about this basket is to imagine the space stack as layers: access to orbit, sensing, communications, infrastructure and exploration. Each of the ten names here owns a useful slice of that stack, often in niches that the mega-caps either do not want or cannot address efficiently.
Top 10 Us Defense Stocks With Real Growth Optionality
The big defense primes will always dominate the headlines, but the real optionality for capital gains usually sits one step below, in the names that own a niche. In this basket the niches are clear: tactical drones and loitering munitions (KTOS, AVAV), hypersonic testing and missile-defense space constellations (KTOS, RKLB), naval power and combat systems (DRS), training and simulation (CAE), advanced composites (HXL), electronic-warfare computers (MRCY), spectrum and cyber for national security (CACI, SAIC) and high-margin aerospace components (HEI).
Outlook Therapeutics Inc ($OTLK)
A post-CRL, post-Type A meeting request deep dive on ONS-5010/LYTENAVA, EU/UK launch reality, funding pressure and how much option value is left in a sub-$35M market cap.
Top 10 Biotech Stocks to Watch in H1 2026 — PDUFA Dates & Catalysts
Big Pharma is heading into a new patent cliff while its in-house pipelines struggle to keep up. That makes small and mid-cap biotech one of the most fertile hunting grounds for both acquisitions and high-beta “run-up” trades ahead of binary events like FDA decisions and pivotal clinical readouts. In this note we highlight ten US-listed biotech names under roughly $2 billion in market cap that all have a clearly defined catalyst between now and the end of June 2026.
Space Stocks in Free Fall
In the last 30 days the “space trade” has flipped from poster child of risk-on to textbook case of brutal risk-off. Launch, satcom and geospatial names are bleeding double-digit days, while some defense-linked players hold up. Under the surface, it is a story of funding, dilution anxiety, macro rates and a sector where AI and defense still pull in structural demand.
Neumora Therapeutics Inc ($NMRA) Feb 12 2026
Key idea. In January we framed Neumora as a post-crash special situation: a neuroscience platform that had just blown up its lead asset navacaprant in Phase 3 MDD, wiping out about 80% of the market cap in one session, but still sitting on a sizeable cash pile and a broad pipeline. The weeks since then have added three crucial pieces: (1) full Phase 1b signal-seeking data for NMRA-511 in Alzheimer’s agitation, (2) a more detailed 2026 pipeline strategy, and (3) better visibility on ownership, institutional support and analyst appetite post-crash. This second deep dive doesn’t repeat the full story — it extends it and tries to answer a simple question: is NMRA slowly rebuilding a credible equity story, or just trading on residual hope and short-term speculation?